Showing 7071-7080 of 8649 results for "".
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed
- Oculus Unveils Pentacam Cornea OCThttps://modernod.com/news/oculus-unveils-pentacam-cornea-oct-at-escrs-2024/2482425/Oculus is introducing the Pentacam Cornea OCT, a tool that combines Scheimpflug technology with the world’s first pericentric OCT scanning system, according to a company news release. The device provides cornea specialists with imaging capabilities, capturing both Scheimpflug
- Samsara Vision Promotes Jason Herod to Chief Commercial Officerhttps://modernod.com/news/samsara-vision-promotes-jason-herod-to-chief-commercial-officer/2482421/Samsara Vision announced that Jason Herod, formerly Vice President Commercial, International Markets, has been promoted to Chief Commercial Officer (CCO), effective August 15, 2024. Mr. Herod joined Samsara Vision in August 2021, bringing with him over 24 years of extensive experi
- Haag-Streit Introduces METIS Ophthalmic Microscope Systemhttps://modernod.com/news/haag-streit-unveils-metis-ophthalmic-microscope-system/2482418/Haag-Streit has introduced the METIS ophthalmic microscope system, which is designed to provide optical performance, ergonomic design, and advanced features tailored for precision and efficiency. Superior Optical Experience The METIS microscope integrates Haag
- Injectsense Completes First Successful Human Implant of Ultraminiature Intraocular Pressure Sensorhttps://modernod.com/news/injectsense-completes-first-successful-human-implant-of-ultraminiature-intraocular-pressure-sensor/2482413/Injectsense has announced the completion of the first human implant and subsequent wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation. The IOP-Connect system study is being conducted under the leadership
- Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://modernod.com/news/study-targets-early-signs-of-vision-loss-in-diabetic-patients/2482408/The University of Houston (UH) College of Optometry is embarking on a study, backed by a $3.3 million grant from the National Eye Institute, to investigate the progression of vision loss in patients with prediabetes and diabetes. The study, led by Associate Professor Wendy Harrison, aims to ident
- Opus Genetics Receives FDA Rare Pediatric Disease Designation for Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-receives-fda-rare-pediatric-disease-designation-for-gene-therapy-opgx-lca5/2482403/Opus Genetics announced that the FDA has granted rare pediatric disease (RPD) designation for its ocular gene therapy, OPGx-LCA5. This therapy is designed to treat patients with Leber congenital amaurosis (LCA) type 5, a rare inherited retinal disease caused by biallelic mutations in th
- Lenz Therapeutics Submits NDA for LNZ100 Eye Drop for Presbyopiahttps://modernod.com/news/lenz-therapeutics-submits-new-drug-application-for-lnz100-eye-drop-for-presbyopia-treatment/2482397/Lenz Therapeutics has submitted a new drug application (NDA) to the FDA for LNZ100, an investigational presbyopia eye drop. This aceclidine-based ophthalmic solution is designed to improve near vision in people with presbyopia. The NDA submission follows the successful completion o
- Study Examines Effectiveness of Injection of Retinal Progenitor Cells (RPCs) in Treating Photoreceptor Degenerationhttps://modernod.com/news/study-examines-effectiveness-of-injection-of-retinal-progenitor-cells-rpcs-in-treating-photoreceptor-degeneration/2482387/A preclinical study demonstrates the effectiveness of intravitreal injection of retinal progenitor cells (RPCs) (jCell) in treating photoreceptor degeneration. The research, from the Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center at the University of